SUBSCRIBE
SUBSCRIBE

Aro Biotherapeutics

NEWS
Courtesy of Sarah Silbiger/Getty Images
Policy
FDA Review: Abiomed, Mallinckrodt, Aro and More
The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.
September 16, 2022
 · 
3 min read
 · 
Mark Terry
Sarah Silbiger/Getty Images
FDA
FDA Review: Bayer, Daiichi Sankyo, AstraZeneca and More
Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.
August 12, 2022
 · 
3 min read
 · 
Mark Terry
Business
Top Life Sciences Startups to Watch in 2022
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
January 4, 2022
 · 
19 min read
 · 
Heather McKenzie
Business
Top 10 US Biopharma Series A Rounds of 2021 – So Far!
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
September 24, 2021
 · 
4 min read
 · 
Ellen Bombela
AWARDS
  • NextGen Class of 2022
JOBS
IN THE PRESS
Press Releases
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
February 11, 2025
 · 
4 min read
Press Releases
Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD)
February 5, 2025
 · 
4 min read
Press Releases
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)
January 23, 2025
 · 
4 min read
Press Releases
Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer
January 7, 2025
 · 
3 min read
Press Releases
Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)
October 29, 2024
 · 
3 min read
Pharm Country
Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting
February 6, 2024
 · 
3 min read
Business
Aro Biotherapeutics Secures $41.5M Series B Financing
November 28, 2023
 · 
2 min read
Pharm Country
Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease
October 25, 2023
 · 
2 min read
Pharm Country
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease
August 10, 2022
 · 
2 min read
Drug Development
Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease
May 11, 2022
 · 
4 min read
Load More